As the community ages, the prevalence of intelligent dysfunction increases, making it a major community health concern. Biomarkers that can detect intelligent dysfunction early may supply a window for attacks that could delay or avert its progress. This review article tests the current state of biomarker research for cognitive dysfunction, containing structural and working neuroimaging, cerebrospinal fluid biomarkers, and blood-located biomarkers. It discusses the strengths and disadvantages of each type of biomarker and highlights hopeful new areas of research. The item also explains challenges in developing biomarkers for intelligent dysfunction, such as the lack of consent on diagnostic tests and the need for large, long-term studies. Overall, the review highlights the potential of biomarkers to boost the diagnosis and situation of cognitive dysfunction and the need for resumed research in this area.

Author(s) Details:

Jerin James,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.

Jamuna Rani,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.

V. Sathyanarayanan,
Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamilnadu, India.

Please see the link here: https://stm.bookpi.org/RPST-V9/article/view/10296

Keywords: Alzheimer’s, biomarkers, cognitive dysfunction, neuroimaging

Leave a Reply

Your email address will not be published. Required fields are marked *